Carole Huntsman - 03 Mar 2025 Form 4 Insider Report for MADRIGAL PHARMACEUTICALS, INC. (MDGL)

Signature
/s/ Mardi Dier, as Attorney-in-Fact
Issuer symbol
MDGL
Transactions as of
03 Mar 2025
Net transactions value
-$597,840
Form type
4
Filing time
05 Mar 2025, 16:24:29 UTC
Previous filing
27 Jan 2025
Next filing
07 Mar 2025

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MDGL Common Stock Sale $22,229 -71 -0.68% $313.08 10,367 03 Mar 2025 Direct F1
transaction MDGL Common Stock Sale $62,948 -200 -1.9% $314.74 10,167 03 Mar 2025 Direct F1, F2
transaction MDGL Common Stock Sale $96,063 -300 -3% $320.21 9,867 03 Mar 2025 Direct F1, F3
transaction MDGL Common Stock Sale $64,730 -200 -2% $323.65 9,667 03 Mar 2025 Direct F1, F4
transaction MDGL Common Stock Sale $64,918 -200 -2.1% $324.59 9,467 03 Mar 2025 Direct F1, F5
transaction MDGL Common Stock Sale $32,634 -100 -1.1% $326.34 9,367 03 Mar 2025 Direct F1
transaction MDGL Common Stock Sale $32,749 -100 -1.1% $327.49 9,267 03 Mar 2025 Direct F1
transaction MDGL Common Stock Sale $32,964 -100 -1.1% $329.64 9,167 03 Mar 2025 Direct F1
transaction MDGL Common Stock Sale $188,605 -563 -6.1% $335.00 8,604 03 Mar 2025 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 These sales were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 5, 2024.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $314.40 to $315.08, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $320.13 to $320.32, inclusive.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $323.47 to $323.83, inclusive.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $324.48 to $324.70, inclusive.